èšåºæ®µéã®ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Exicure, Inc. ã¯ãç¬èªã®çç¶æ žé
ž (SNA) æè¡ã«åºã¥ããŠãç¥çµåŠãå
ç«è
«çåŠãççæ§çŸæ£ãéºäŒæ§çŸæ£ã®æ²»çè¬ãéçºããŠããŸãããã®åè£è¬ã«ã¯ãé²è¡æ§åºåœ¢è
«çã®æ£è
ã察象ã«ç¬¬ 1b/2 çžèšåºè©Šéšãè¡ãããŠãã cavrotolimod (AST-008) ããããŸããå瀟ã¯ãŸããããªãŒãã©ã€ãéå倱調çã®æ²»çè¬ãšããŠåèšåºè©Šéšãè¡ãããŠãã SNA ããŒã¹ã®æ²»çè¬åè£ XCUR-FXNãã€ã³ã¿ãŒãã€ãã³ 17 å容äœã¢ã«ãã¡ãã³ãŒãããã¡ãã»ã³ãžã£ãŒ RNA (mRNA) ãæšçãšãã SNA XCUR17ã軜床ããäžç床ã®ä¹Ÿç¬ã®æ²»çè¬ãšã㊠TNF ãæšçãšãã SNA AST-005 ãéçºããŠããŸããå瀟㯠Allergan Pharmaceuticals International Limited ãšææºããªãã·ã§ã³ãã©ã€ã»ã³ã¹å¥çŽãç· çµããè±æ¯çã® SNA ããŒã¹ã®æ²»çè¬ãéçºããŠããŸãã DERMELIX, LLC ãšã®ã©ã€ã»ã³ã¹ããã³éçºå¥çŽã«ããããã¶ãŒãã³çåçŸ€ã®æ²»çã®ããã®æè¡ãç ç©¶ãéçºãåååããŸãããŸããIpsen SA ãšã®ååå¥çŽã«ããããã³ãã³ãã³ç
ããã³ã¢ã³ãžã§ã«ãã³çå矀ã®ããã®æ°ããçç¶æ žé
žãç ç©¶ãéçºãåååããŸããå瀟㯠2011 幎ã«èšç«ãããã€ãªãã€å·ã·ã«ãŽã«æ¬ç€Ÿã眮ããŠããŸãã